Neurotensin

What is Neurotensin?

Neurotensin is an endogenous 13-amino-acid neuropeptide (pyroGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu) isolated and named in 1973 by Robert Carraway and Susan Leeman at Brandeis University, who purified it from bovine hypothalamic extracts during a substance-P fractionation campaign and noticed a peripheral hypotensive activity in the unrelated fractions — the 'neuro-tensin' name records the dual provenance of central nervous system origin and peripheral vascular effect. The 1975 Journal of Biological Chemistry paper from the same group reported the full amino-acid sequence, and a parallel paper from Lazarus, Brown, and colleagues in the same issue described its synthesis. The C-terminal hexapeptide (residues 8-13) carries the receptor-binding pharmacophore, and the C-terminal Leu-OH free carboxyl is critical for activity. Neurotensin is generated by processing of a 170-residue precursor (preproneurotensin/neuromedin N), which also yields the related hexapeptide neuromedin N. It signals through three identified receptors with very different architectures: NTS1 (NTSR1), the high-affinity G-protein-coupled receptor cloned by Tanaka and colleagues from rat brain in 1990 and by Vita and colleagues from human brain shortly after; NTS2 (NTSR2), the lower-affinity, levocabastine-sensitive GPCR cloned by Chalon and colleagues in 1996; and sortilin (NTS3/SORT1), a single-transmembrane sorting receptor unrelated to GPCRs, identified in 1998 by Mazella and colleagues as a Vps10p-domain protein that binds neurotensin with high affinity but predominantly traffics ligands to intracellular compartments. Neurotensin is widely distributed in the central nervous system (notably the hypothalamus, nucleus accumbens, ventral tegmental area, substantia nigra, and amygdala) and the gastrointestinal tract (N-cells of the distal small intestine), where it functions as a neuromodulator centrally and as a circulating gut hormone peripherally. Centrally, its tightest biological story is interaction with dopaminergic systems — antipsychotic-like behavioral effects in animals, dopamine-modulating circuitry in the mesolimbic pathway, and altered cerebrospinal-fluid neurotensin in subsets of patients with schizophrenia. Peripherally, it produces hypotension, hypothermia, and gastric-motility effects on intravenous infusion in animals, and is an established gut hormone modulating fat absorption and intestinal trophic responses. Drug-discovery interest has focused on NTS1 agonists for schizophrenia (PD149163 and related brain-penetrant analogs) and NTS1-targeted radioligand and chemotherapy strategies in pancreatic and small-cell lung cancers, where NTS1 is overexpressed.

What Neurotensin Is Investigated For

Neurotensin is an endogenous-biology and drug-target topic, not a peptide that consumers take. Its scientific footprint splits into three connected stories. The first is the dopamine and schizophrenia connection: neurotensin is densely co-expressed with dopamine in mesolimbic and nigrostriatal circuits, NTS1 agonists produce antipsychotic-like behavioral effects in rodents (suppression of amphetamine-induced hyperlocomotion, normalization of prepulse inhibition deficits, reversal of social-interaction deficits) without the extrapyramidal side effects of D2 antagonists, and Charles Nemeroff and collaborators reported altered cerebrospinal-fluid neurotensin concentrations in subsets of patients with schizophrenia in the 1980s — a body of work that has anchored decades of medicinal chemistry on brain-penetrant NTS1 agonists like PD149163, NT69L, and PD149163-related analogs. None has reached approval. The second is the cancer story: NTS1 is overexpressed on pancreatic ductal adenocarcinoma, small-cell lung cancer, colorectal cancer, breast cancer, and other epithelial tumors, providing a tumor-selective handle for radioligand therapy (lutetium-177 or copper-64 labeled NT analogs), neurotensin-coupled chemotherapy, and antibody-drug conjugates. Several radioligand candidates have advanced to early-phase clinical evaluation in NTS1-positive tumors. The third is the peripheral physiology: neurotensin is a gut hormone secreted by N-cells of the distal small intestine in response to luminal fat, and it modulates fat absorption, intestinal motility, and pancreaticobiliary secretion — work that has connected gut neurotensin to metabolic phenotypes including obesity. Across all three stories, the common thread is that neurotensin's pharmacology is rich and its translational chapter is mostly unfinished.

History & Discovery

Neurotensin was isolated and named in 1973 by Robert Carraway and Susan Leeman at Brandeis University. The discovery was a serendipitous byproduct of a substance-P purification campaign — Carraway and Leeman were fractionating bovine hypothalamic extracts in pursuit of substance P and noticed that side fractions, distinct from the substance-P-active material, produced striking peripheral effects (cutaneous vasodilation, hypotension) on intravenous injection in rats. They followed the bioactivity, purified the responsible molecule, and named it 'neuro-tensin' to record its dual provenance: a peptide of central nervous system origin (hypothalamic) with peripheral vascular ('-tensin') activity. The 1973 Journal of Biological Chemistry paper reported the isolation; the 1975 paper from the same group reported the full 13-residue amino-acid sequence; and a parallel 1975 paper from Lazarus, Brown, and colleagues described the chemical synthesis. The receptor pharmacology unfolded over the following two decades. The high-affinity NTS1 (NTSR1) was cloned from rat brain by Kazutoshi Tanaka, Masayuki Masu, and Shigetada Nakanishi at Kyoto University in 1990 (Neuron), demonstrating the seven-transmembrane GPCR architecture and Gq-mediated phosphoinositide signaling. The lower-affinity, levocabastine-sensitive NTS2 (NTSR2) was cloned from rat brain by Pierre Chalon, Daniel Caput, and colleagues at Sanofi in 1996 (FEBS Letters). The longstanding puzzle of the high-molecular-weight 100-kDa neurotensin-binding site was solved in 1998 when Jean Mazella and colleagues at the CNRS Institute of Molecular and Cellular Pharmacology in Valbonne identified it as gp95/sortilin (Journal of Biological Chemistry) — a single-transmembrane Vps10p-domain sorting receptor structurally unrelated to GPCRs that subsequently emerged as a multifunctional trafficking receptor for proneurotrophins, progranulin, and lipoprotein ligands. Functional and translational work proceeded in parallel. Garth Bissette, Charles Nemeroff, and colleagues at Duke and later Emory established the centrally-mediated hypothermic and analgesic effects of neurotensin in animal models in the 1970s, and developed the cerebrospinal-fluid neurotensin biomarker work in schizophrenia in the 1980s. Sanofi medicinal chemistry produced the first nonpeptide NTS1 antagonist, SR48692, reported by Daniel Gully and colleagues in 1993 (PNAS), which became a workhorse research tool and was followed by the dual NTS1/NTS2 antagonist SR142948A. Brain-penetrant NTS1 agonists like PD149163 (Parke-Davis), NT69L (Mona Boules and Elliott Richelson at Mayo Clinic), and stabilized NT8-13 analogs were developed across the 1990s and 2000s as candidates for schizophrenia, drug abuse, and pain — producing consistent preclinical antipsychotic-like signals but no approved drug. The oncology angle developed in parallel: Jean Claude Reubi, Beatrice Waser, and colleagues in Bern documented marked NTS1 overexpression in pancreatic ductal adenocarcinoma and other tumors (1999-2000), seeding the radioligand-therapy strategies that have advanced into early-phase clinical trials in NTS1-positive cancers. As of 2026, no neurotensin or neurotensin-receptor-targeted drug has reached approval for any indication, but multiple investigational candidates remain in active development.

How It Works

Neurotensin is a small protein the body makes both in the brain and in the gut. In the brain, it sits next to the dopamine system — the same system targeted by antipsychotic drugs — and seems to dampen overactive dopamine signaling in animal models, which is why drugs that activate its receptor look antipsychotic-like in rodents. In the gut, it is released by cells in the small intestine when fat hits them, and it tells the intestine to absorb fat and slow down a bit. It also lowers blood pressure, drops body temperature, and produces a kind of pain relief that doesn't go through the opioid system. It works by docking onto three different receptors: two of them are normal G-protein-coupled receptors (NTS1, NTS2), and the third (sortilin) is a totally different kind of receptor that drags neurotensin inside the cell instead of sending a signal outward. Cancer drug developers have noticed that pancreatic and lung tumors carry a lot of NTS1 on their surface, so they are building neurotensin-shaped molecules that deliver radiation or chemotherapy directly to those tumors.

Neurotensin is a 13-amino-acid peptide (pyroGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu) generated by post-translational processing of a 170-residue preproneurotensin/neuromedin N precursor. The C-terminal hexapeptide (NT8-13) carries the full receptor-binding pharmacophore, and the free C-terminal carboxyl is essential for high-affinity binding — modifications at the C-terminus typically abolish receptor activity. Native neurotensin is rapidly degraded by neutral endopeptidase (neprilysin), endopeptidase-24.16 (neurolysin), and angiotensin-converting enzyme through cleavage at multiple internal Pro-Arg, Arg-Arg, and Tyr-Ile bonds, giving a plasma half-life on the order of seconds to a few minutes — a major reason that translational efforts have focused on stabilized backbone-modified analogs. Three receptors mediate neurotensin's biology, with very different architectures. NTS1 (NTSR1, encoded by NTSR1) is a class-A rhodopsin-family G-protein-coupled receptor cloned by Tanaka and colleagues from rat brain in 1990 (Neuron), with high affinity for neurotensin (low-nanomolar Kd). It couples primarily to Gq/11, activating phospholipase C beta, generating inositol trisphosphate and diacylglycerol, and mobilizing intracellular calcium; depending on cell context it also engages Gi/o and Gs pathways and activates MAP-kinase signaling. NTS1 is densely expressed in the substantia nigra, ventral tegmental area, nucleus accumbens, hypothalamus, intestine, and on a range of epithelial tumors. It mediates most of neurotensin's classically described effects, including dopaminergic modulation, antipsychotic-like behavior with NTS1 agonists, hypotension, gut-motility effects, and tumor signaling. NTS2 (NTSR2) is a related class-A GPCR cloned by Chalon and colleagues in 1996 (FEBS Letters) from a rat brain library, with lower affinity for neurotensin and notable sensitivity to the H1-antihistamine levocabastine — the latter property historically distinguished it before molecular cloning. NTS2 couples to Gq and Gi/o and mediates analgesic and some thermal effects of neurotensin, with anatomical enrichment in the spinal cord, periaqueductal gray, and cerebellum. NTS3, also called sortilin (encoded by SORT1), is structurally unrelated to GPCRs — it is a 95-kDa type-I single-transmembrane Vps10p-domain protein, identified by Mazella and colleagues in 1998 (Journal of Biological Chemistry) as the long-known '100-kDa neurotensin-binding site.' Sortilin binds neurotensin with high affinity but does not initiate canonical G-protein signaling; instead, it functions as a sorting receptor that traffics ligands between the cell surface, Golgi, and lysosome, and it has subsequently emerged as a multifunctional receptor for proneurotrophins (proNGF, proBDNF), progranulin, and lipoprotein-related ligands, with broader roles in neuronal survival and lipid metabolism that extend beyond neurotensin biology. Functionally, central neurotensin acting at NTS1 modulates dopaminergic neurons in the ventral tegmental area and substantia nigra, with effects on mesolimbic and nigrostriatal transmission that underlie the antipsychotic-like behavioral profile of brain-penetrant NTS1 agonists like PD149163 (suppression of amphetamine-induced hyperlocomotion, restoration of prepulse inhibition, reversal of social-interaction deficits in rodent schizophrenia models). Centrally administered neurotensin produces hypothermia and analgesia distinct from opioid mechanisms (resistant to naloxone), with the analgesic effect mediated in part through NTS2. Peripherally, neurotensin is secreted by N-cells of the distal small intestine in response to luminal fat and acts as an enterocrine hormone modulating fat absorption, intestinal motility, and pancreaticobiliary secretion — work that has connected circulating neurotensin to obesity-related phenotypes. Intravenous infusion produces systemic hypotension through vasodilation. In oncology, NTS1 is overexpressed on pancreatic ductal adenocarcinoma, small-cell lung cancer, colorectal cancer, and other epithelial tumors, where receptor activation drives proliferation, invasion, and resistance signaling — and the same overexpression provides the tumor-selective handle for radioligand and antibody-drug-conjugate strategies. The first nonpeptide NTS1 antagonist, SR48692, was reported by Gully and colleagues in 1993 (PNAS) and remains a workhorse pharmacological tool, alongside the dual NTS1/NTS2 antagonist SR142948A.

Evidence Snapshot

Research Gaps & Open Questions

What the current literature has not yet settled about Neurotensin:

• 01Whether brain-penetrant NTS1 agonists can deliver clinically meaningful antipsychotic efficacy in humans — three decades of preclinical schizophrenia-model work has produced consistent signals but no approved drug, and the translational chapter remains the central unresolved question of CNS neurotensin pharmacology.
• 02Whether NTS1-targeted radioligand therapy (lutetium-177, copper-64, or other radionuclide-conjugated NT analogs) can deliver durable clinical responses in NTS1-positive pancreatic, small-cell lung, and colorectal cancers — early-phase trials are underway but mature efficacy data remain limited.
• 03The directional role of sortilin (NTS3) in neurotensin biology versus its now-better-characterized roles in proneurotrophin trafficking, progranulin biology, and lipid metabolism — whether NT/sortilin signaling is functionally important in vivo or whether sortilin's NT-binding activity is a vestigial property overshadowed by other ligand interactions.
• 04Whether circulating neurotensin (the gut-hormone pool) is causally involved in human obesity and metabolic disease, or merely a biomarker — Mendelian-randomization and intervention studies have produced suggestive but not yet definitive answers.
• 05The clinical relevance of cerebrospinal-fluid neurotensin alterations in schizophrenia and other psychiatric disorders — whether these represent disease-relevant signals, pharmacodynamic markers, or epiphenomena.
• 06Whether NTS2-selective agonists can deliver clinically meaningful non-opioid analgesia in humans — preclinical data are encouraging but no NTS2-selective ligand has reached clinical evaluation as an analgesic.
• 07The full structural pharmacology of NTS1 in different functional states (active, inactive, biased) — recent crystal and cryo-EM structures have advanced understanding but the implications for biased agonist design remain incompletely worked out.

Forms & Administration

Neurotensin is not formulated or approved as a therapeutic in any jurisdiction. Research applications use synthetic neurotensin (NT1-13) and the bioactive C-terminal hexapeptide (NT8-13) for in vitro receptor binding and signaling assays, ex vivo tissue pharmacology, and intracerebroventricular, intrathecal, or intravenous administration in animal models. Stabilized backbone-modified NT analogs (e.g., NT8-13 variants with reduced peptide bonds, D-amino-acid substitutions, or conjugation strategies) exist as research tools and investigational compounds — designed to overcome the very short plasma half-life of native NT. Brain-penetrant NTS1 agonists like PD149163, NT69L, and related analogs are research compounds used in animal psychiatric models. NT-radioligand conjugates (lutetium-177, copper-64, technetium-99m, and gallium-68 labeled NT analogs) are investigational oncology agents used in early-phase imaging and therapeutic trials in NTS1-positive tumors. Compounded neurotensin from peptide marketplaces has no validated clinical use.

Common Questions

Who Neurotensin Is NOT For

Drug & Supplement Interactions

There is no validated human drug-interaction profile for neurotensin because no neurotensin product has been clinically developed for chronic use. Theoretical interactions follow from neurotensin's known signaling: at NTS1 receptors, neurotensin agonism modulates dopaminergic transmission and could in principle interact with antipsychotic medications (haloperidol, risperidone, olanzapine, aripiprazole, clozapine), psychostimulants (amphetamine, methylphenidate), and dopamine-replacement agents used in Parkinson's disease (levodopa, dopamine agonists) — particularly relevant given that PD149163 and other brain-penetrant NTS1 agonists have demonstrated antipsychotic-like effects in animal models that overlap mechanistically with D2 antagonists. Peripheral neurotensin produces vasodilation and hypotension, with potential interaction with antihypertensives, vasodilators, alpha-blockers, and phosphodiesterase-5 inhibitors. Gastrointestinal effects on motility could theoretically interact with prokinetic agents (metoclopramide, prucalopride), opioids (which slow gut transit), and proton-pump inhibitors (which alter the upper GI environment). At NTS2, neurotensin produces non-opioid analgesia that could theoretically interact with opioid analgesics, NSAIDs, or gabapentinoids. None of these interactions has been characterized in controlled human studies; they are mechanistic possibilities that argue against casual exogenous neurotensin exposure rather than documented clinical events.

Safety Profile

Legal Status

Regulatory status changes over time. Verify current local rules with a qualified professional.

Myths & Misconceptions